コンテンツへスキップ
Merck

PTK7 is a positive allosteric modulator of GPR133 signaling in glioblastoma.

Cell reports (2023-06-24)
Joshua D Frenster, Hediye Erdjument-Bromage, Gabriele Stephan, Niklas Ravn-Boess, Shuai Wang, Wenke Liu, Devin Bready, Jordan Wilcox, Björn Kieslich, Manuel Jankovic, Caroline Wilde, Susanne Horn, Norbert Sträter, Ines Liebscher, Torsten Schöneberg, David Fenyo, Thomas A Neubert, Dimitris G Placantonakis
要旨

The adhesion G-protein-coupled receptor GPR133 (ADGRD1) supports growth of the brain malignancy glioblastoma. How the extracellular interactome of GPR133 in glioblastoma modulates signaling remains unknown. Here, we use affinity proteomics to identify the transmembrane protein PTK7 as an extracellular binding partner of GPR133 in glioblastoma. PTK7 binds the autoproteolytically generated N-terminal fragment of GPR133 and its expression in trans increases GPR133 signaling. This effect requires the intramolecular cleavage of GPR133 and PTK7's anchoring in the plasma membrane. PTK7's allosteric action on GPR133 signaling is additive with but topographically distinct from orthosteric activation by soluble peptide mimicking the endogenous tethered Stachel agonist. GPR133 and PTK7 are expressed in adjacent cells in glioblastoma, where their knockdown phenocopies each other. We propose that this ligand-receptor interaction is relevant to the pathogenesis of glioblastoma and possibly other physiological processes in healthy tissues.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
4′,6-ジアミジノ-2-フェニルインドール 二塩酸塩, powder, BioReagent, suitable for cell culture, ≥98% (HPLC and TLC), suitable for fluorescence